Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables

Pharmacopsychiatry

Volumn 41, Issue 3, 2008, Pages 81-91

  Diaz, F J ^a   Santoro, V ^b   Spina, E ^b   Cogollo, M ^a   Rivera, T E ^c   Botts, S ^d   De Leon, J ^d  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSIDAD INDUSTRIAL DE SANTANDER   (Colombia)

^d EASTERN STATE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; NORCLOZAPINE; PAROXETINE; PHENOBARBITAL; REBOXETINE; SERTRALINE; VALPROIC ACID;

ADULT; ARTICLE; DRUG BLOOD LEVEL; DRUG EFFECT; GENDER; HUMAN; MAJOR CLINICAL STUDY; MODEL; PRIORITY JOURNAL; SMOKING; STEADY STATE;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HUMANS; LINEAR MODELS; MALE; PSYCHOTIC DISORDERS; REFERENCE VALUES; WEIGHTS AND MEASURES;

EID: 44849135619     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1004591     Document Type: Article

References (58)

1. Avenoso A, Facciolo G, Campo GM, Fazio A, Spina E. Determination of clozapine, desmethylclozapine and clozapine N-oxide in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1998; 714: 299-308
2. Avenoso A, Facciolà G, Scordo MG, Gitto C, Drago Ferrante G, Madia AG et al. No effect of citalopram on plasma levels of clozapine, risperidone and their active metabolites in patients with schizophrenia. Clin Drug Invest 1998; 16: 393-398
3. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gertach M et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37: 243-256
4. Brown H, Prescott R. Applied mixed models in medicine. Hoboken, NJ: John Wiley & Sons 2001
5. Centorrino F, Baldessarini RJ, Kando JC, Frankenburg FR, Volpicelli SA, Flood JG. Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacol 1994; 14: 119-125
6. Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Puopolo PR et al. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry 1994; 151: 123-125
7. Conca A, Beraus W, Konig P, Waschgler R. A case of pharmacokinetic interference in comedication of clozapine and valproic acid. Pharmacopsychiatry 2000; 33: 234-235
8. Davidian M, Giltinan DM. Nonlinear models for repeated measurement data. Boca Raton, FL: Chapman & Hall/CRC 1995
9. de Leon J. Glucuronidation enzymes, genes and psychiatry. Int J Neuropsychopharmacology 2003; 6: 57-72
10. de Leon J. Psychopharmacology. Atypical antipsychotic dosing: The effect of co-medication with anticonvulsants. Psychiatr Serv 2004; 55: 125-128
11. de Leon J. Psychopharmacology. Atypical antipsychotic dosing: the effect of smoking and caffeine. Psychiatr Serv 2004; 55: 491-493
12. de Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics 2005; 46: 262-273
13. de Leon J, Diaz FJ. Serious respiratory infections can increase clozapine levels and contribute to side effects: A case report. Prog Neuro-Psychopharmacol Biol Psychiatry 2003; 27: 1059-1063
14. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005; 76: 135-157
15. de Leon J, Diaz FJ, Josiassen RC, Cooper TB, Simpson GM. Does clozapine decrease smoking? Prog Neuro-Psychopharmacol Biol Psychiatry 2005; 29: 757-762
16. de Leon J, Diaz FJ, Josiassen RC, Cooper TB, Simpson GM. Weight gain during a double-blind multi-dosage clozapine study. J Clin Psychopharmacol 2007; 127: 22-27
17. de Leon J, Diaz F, Rogers T, Browne D, Dinsmore L, Ghosheh O et al. A pilot study of plasma caffeine concentrations in a US sample of smokers and non-smokers volunteers. Prog Neuro-Psychopharmacol Biol Psychiatry 2003; 27: 165-171
18. de Leon J, Odom-White A, Josiassen RC, Diaz FJ, Cooper TB, Simpson GM. Serum muscarinic activity during clozapine treatment. J Clin Psychopharmacology 2003; 23: 336-341
19. de Leon J, Susce MT, Johnson M, Hardin M, Pointer L, Ruaño C et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr Res 2007; 92: 95-102
20. de Leon J, Susce MT, Pan RM, Wedlund PJ, Orrego ML, Diaz FJ. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 2007; 40: 93-102
21. Dettling M, Sachse C, Brockmoller J, Schley J, Mueller-Oerlinghausen B, Pickersgill I et al. Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients. Psychopharmacology 2000; 152: 80-86
22. Diaz FJ, Rivera TE, Josiassen RC, de Leon J. Individualizing drug dosage by using a random intercept linear model. Statist Med 2007; 26: 2052-2073
23. Facciolà GA, Avenoso E, Spina E, Perucca E. Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia. Ther Drug Monit 1998; 20: 628-630
24. Facciola G, Avenoso A, Scordo MG, Madia AG, Ventimiglia A, Perucca E et al. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Ther Drug Monit. 1999; 21: 341-345
25. Finley P, Warner D. Potential impact of valproic acid therapy on clozapine disposition. Biol Psychiatry 1994; 36: 487-488
26. Haring C, Meise U, Humpel C, Saria A, Fleishhacker WW, Hinterhuber H. Dose-related plasma levels of clozapine: influence of smoking behavior, sex and age. Psychopharmacology 1989; 99: S38-S40
27. Haring C, Fleischhacker WW, Schett P, Humpel C, Barnas C, Saria A. Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry 1990; 147: 1471-1475
28. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: Effect of smoking. J Clin Psychopharmacol 1993; 13: 383-390
29. Haslemo T, Eikeseth PH, Tanum L, Molden E, Refsum H. The effect of variable consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol 2006; 62: 1049-1053
30. Hendset M, Haslemo T, Rudberg I, Refsum H, Molden E. The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry 2006; 39: 121-127
31. Hiemke C, Weighmann H, Hartter S, Dahmen N, Wetzel H, Muller H. Elevated serum levels of clozapine after addition of fluvoxamine (letter). J Clin Psychopharmacol 1994; 14: 279-281
32. Hiemke C, Dragicevic A, Grunder G, Hatter S, Sachse J, Vernaleken I et al. Therapeutic drug monitoring of new antipsychotic drugs. Ther Drug Monit 2004; 26: 156-160
33. Kronig MH, Munne RH, Szymanski S, Safferman AZ, Pollack S, Cooper T et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 1995; 152: 179-182
34. 1C receptor antagonists. Eur J Pharmacol-Mol Pharmacol Section 1993; 245: 179-182
35. Lane HY, Chang YC, Lin SK, Tseng YT, Jann MW. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry 1999; 60: 36-40
36. Littell RC, Milliken GA, Stroup WW, Wolfinger RD, Schabenberger O. SAS for Mixed Models. Second Edition. Cary, NC: SAS Institute Inc. 2006
37. Longo LP, Salzman C. Valproic acid effects on serum concentrations of clozapine and norclozapine. Am J Psychiatry 1995; 152: 650
38. Lu ML, Lane HY, Lin SK, Chen KP, Chang WH. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 2004; 65: 766-771
39. Ozdemir V, Kalow W, Posner P, Collins EJ, Kennedy JL, Tang BK et al. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite norclozapine steady-state concentration in patients with schizophrenia. J Clin Psychopharmacol 2002; 21: 398-407
40. Palego L, Biondi L, Giannaccini G, Sarno N, Elmi S, Ciapparelli A et al. Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables. Prog Neuro-Psychopharmacol Biol Psychiatry 2002; 26: 473-480
41. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenia patients. Am J Psychiatry 1991; 148: 231-235
42. Perry PJ, Bever KA, Arndt S, Combs MD. Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. Biol Psychiatry 1998; 44: 733-738
43. Pinninti NR, de Leon J. Interaction of sertraline with clozapine (letter). J Clin Psychopharmacology 1997; 17: 119-120
44. Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 2004; 24: 70-78
45. Simpson GM, Josiassen RC, Stanilla JK, de Leon J, Nair C, Abraham G et al. Double-blind study of clozapine dose response in chronic schizophrenia. Am J Psychiatry 1999; 156: 1744-1750
46. Spina E, Avenoso G, Facciolà M, Fabrazzo M, Monteleone P, Maj M et al. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int Clin Psychopharmacol 1998; 13: 141-145
47. Spina E, Avenoso A, Faccioia G, Scordo MG, Ancione M, Madia AG et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology 2000; 148: 83-89
48. Spina E, Avenoso A, Salemi M, Facciola G, Scordo MG, Ancione M et al. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. Pharmacopsychiatry 2000; 33: 213-217
49. Spina E, Avenoso A, Scordo MG, Ancione M, Madia A, Levita A. No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites. Ther Drug Monit 2001; 23: 675-678
50. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Tox 2007; 100: 4-22
51. Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB et al. N-Desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA 2003; 100: 13674-13679
52. Tang YL, Mao P, Li FM, Li W, Chen Q, Jiang F et al. Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia. Br J Clin Pharmacol 2007; 64: 49-56
53. Ulrich S, Baumann B, Wolf R, Lehmann D, Peters B, Bogerts B et al. Therapeutic drug monitoring of clozapine and relapse - a retrospective study of routine clinical data. Int J Clin Pharmacol Ther 2003; 41: 3-13
54. van der Weide J, Steijns LS, van Weelden MJ. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 2003; 13: 169-172
55. VenderZwaag C, MacGee M, MacEvoy JP, Freudenreich O, Wilson WH, Cooper TB. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996; 153: 1579-1584
56. Wong JO, Leung SP, Mak T, Ng RM, Chan KT, Cheung HH et al. Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients. Prog Neuro-Psychopharmacol Biol Psychiatry 2006; 30: 251-264
57. Woodward M. Epidemiology: Study Design and Data Analysis. Chapman & Hall/CRC, Boca Raton, FL 1999
58. Zink M, Englisch S, Knopf U, Kuwilsky A, Dressing H. Augmentation of clozapine with valproic acid for clozapine-induced obsessive-compulsive symptoms. Pharmacopsychiatry 2007; 40: 202-203